Parental Acceptance of a Mandatory Human Papillomavirus (HPV) Vaccination Program

References

1. ↵
   Villa LL, Costa RLR, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1 virus-like particle vaccine in young women: a randomized double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6: 271–8.

   OpenUrlCrossRefPubMedWeb of Science
2. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356: 1915–27.

   OpenUrlCrossRefPubMedWeb of Science
3. Ault KA, FUTURE II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3 and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007; 369: 1861–8.

   OpenUrlCrossRefPubMedWeb of Science
4. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356: 1928–43.

   OpenUrlCrossRefPubMedWeb of Science
5. ↵
   Associated Press. 1 in 4 U.S. girls received HPV vaccine. October 9, 2008. Available at http://www.msnbc.msn.com/id/27103121/ns/health-kids_and_parenting/. Accessed 6 July 2009.
6. Springer K. Why are HPV vaccine rates so low? 25 February 2008. Available at http://www.newsweek.com/id/115329/output/print. Accessed 6 July 2009.
7. ↵
   Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007; 56: 1–24.

   OpenUrlPubMed
8. ↵
   CDC. Coverage estimates for school entry vaccinations, 2007–2008 school year. Available at http://www2.cdc.gov/nip/schoolsurv/nationalavg.asp. Accessed 6 July 2009.
9. ↵
   Ford CA, English A, Davenport AF, Stinnett AJ. Increasing adolescent vaccination: barriers and strategies in the context of policy, legal and financial issues. J Adolesc Health 2009; 44: 568–74.

   OpenUrlCrossRefPubMedWeb of Science
10. Kahn JA, Rosenthal SL, Jin Y, Huang B, Namakydoust A, Zimet GD. Rates of human papillomavirus vaccination, attitudes about vaccination, and human papillomavirus prevalence in young women. Obstet Gynecol 2008; 111: 1103–10.

    OpenUrlCrossRefPubMedWeb of Science
11. Keating KM, Brewer NT, Gottlieb SL, Liddon N, Ludema C, Smith JS. Potential barriers to HPV vaccine provision among medical practices in an area with high rates of cervical cancer. J Adolesc Health 2008; 43: S61–7.

    OpenUrlCrossRefPubMedWeb of Science
12. ↵
    Morita JY, Ramirez E, Trick WE. Effect of a school-entry vaccination requirement on racial and ethnic disparities in hepatitis B immunization coverage levels among public school students. Pediatrics 2008; 121: 547–52.

    OpenUrlAbstract/FREE Full Text
13. Fogarty KJ, Massoudi MS, Gallo W, Averhoff FM, Yusuf H, Fishbein D. Vaccine coverage levels after implementation of a middle school vaccination requirement, Florida, 1997–2000. Public Health Rep 2004; 119: 163–9.

    OpenUrlPubMedWeb of Science
14. Olshen E, Mahon BE, Wang S, Woods ER. The impact of state policies on vaccine coverage by age 13 in an insured population. J Adolesc Health 2007; 40: 405–11.

    OpenUrlCrossRefPubMedWeb of Science
15. Wilson TR, Fishbein DB, Ellis PA, Edlavitch SA. The impact of a school entry law on adolescent immunization rates. J Adolesc Health 2005; 37: 511–6.

    OpenUrlCrossRefPubMedWeb of Science
16. ↵
    Gostin LO, DeAngelis CD. Mandatory HPV vaccination, public health vs private wealth. JAMA 2007; 297: 1921–3.

    OpenUrlCrossRefPubMed
17. ↵
    Horn L, Howard C, Waller JL, Ferris DG. Opinions of parent's about school-entry mandates for the human papillomavirus vaccine. J Lower Genit Tract Dis 2010; 14: 53–8.

    OpenUrl
18. ↵
    Hopson K. Majority of U.S. parents not in favor of HPV vaccine mandates. 22 May 2007. Available at http://www2.med.umich.edu/prmc/media/newsroom/details.cfm?id=532. Accessed 12 January 2010.
19. ↵
    Ferris DG, Waller JL, Miller J, et al. Variables associated with human papillomavirus (HPV) vaccine acceptance by men. J Am Board Fam Med 2009; 22: 34–42.

    OpenUrlAbstract/FREE Full Text
20. Ferris DG, Waller JC, Owen A, Smith J. Human papillomavirus vaccine acceptance among mid-adult women. J Am Board Fam Med 2008; 21: 31–7.

    OpenUrlAbstract/FREE Full Text
21. ↵
    Davis K, Dickman ED, Ferris D, Dias JK. Human papillomavirus vaccine acceptability among parents of 10- to 15-year-old adolescents. J Lower Gen Tract Dis 2004; 8: 188–94.

    OpenUrl
22. ↵
    Ferris DG, Waller JL, Miller J, et al. Men's attitudes toward receiving the Human papillomavirus vaccine. J Lower Gen Tract Dis 2008; 12: 276–81.

    OpenUrl
23. ↵
    Javitt G, Berkowitz D, Gostin LO. Assessing mandatory human papillomavirus vaccination: who should call the shots? J Law Med Ethics 2008; 36: 384–95.

    OpenUrlCrossRefPubMed
24. ↵
    Colgrove J. The ethics and politics of compulsory human papillomavirus vaccination. N Engl J Med 2006; 355: 2389–91.

    OpenUrlCrossRefPubMedWeb of Science
25. ↵
    Field RI, Caplan AL. A proposed ethical framework for vaccine mandates: Competing values and the case of human papillomavirus. Kennedy Inst Ethics J 2008; 18: 111–24.

    OpenUrlCrossRefPubMedWeb of Science
26. ↵
    Haber G, Malow RM, Zimet GD. The human papillomavirus vaccine mandate controversy. J Pediatr Adolesc Gynecol 2007; 20: 325–31.

    OpenUrlCrossRefPubMedWeb of Science